This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Thursday's Winners & Losers: Chindex International

Fortress Investment Group (FIG - Get Report) reworked a deal with Penn National Gaming (PENN - Get Report) Thursday, as financial stocks ticked up slightly ahead of the holiday weekend.

Fortress and private equity firm Centerbridge Partners, which had agreed in June to buy Penn for $67 a share will now instead invest in the casino operator and pay a termination fee. Penn stock had declined 44% since last June. Fortress was trading down about 1% to $11.39; Penn was up 3% to $29.45.

Wachovia (WB - Get Report) dropped 3.1% to $14.90. The bank announced that it appointed Kevin O'Connor as its chief investment officer to Wachovia Global Securities Lending, a division of the bank that handles third-party lending.

Chindex International (CHDX) said Wednesday post close that it received approval from health regulators in the People's Republic of China to introduce new products, including Intuitive Surgical's (ISRG - Get Report) daVinci S. Surgical System. Chindex shares rose 15% to $16.13 Thursday, and Intuitive Surgical's shares edged down 0.2% to $250.57.

Abbott Laboratories (ABT - Get Report) shares climbed on the Food and Drug Administration approval of its Xience V, a drug-eluting stent for patients with coronary artery disease. The antibiotic-coated mesh tube will compete with products by Boston Scientific (BSX - Get Report), Medtronic (MDT) and Johnson & Johnson (JNJ).

Abbott, which said it will launch the stent in the U.S. immediately, saw shares rise 1% to $54.80. Shares of competitor Boston Scientific, which makes the Taxus stent, edged down 4 cents to $12.37.
This article was written by a staff member of

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ABT $38.10 -1.20%
BSX $21.80 0.11%
CHDX $23.99 0.00%
FIG $4.79 -0.42%
ISRG $615.27 -0.54%


Chart of I:DJI
DOW 17,651.26 -99.65 -0.56%
S&P 500 2,052.63 -10.74 -0.52%
NASDAQ 4,730.8550 -32.3690 -0.68%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs